HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G fragrances

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble will terminate a fragrance distribution agreement with Clarins effective Dec. 31, 2005, Clarins announces June 29. French beauty firm has distributed P&G's Hugo Boss, Giorgio, Jean Patou, Lacoste and Valentino brands in the U.S. market for six years. P&G says it has not made any decisions about how the brands will be distributed in the future, but the move follows the acquisition of Wella, which distributes fragrances under its Cosmopolitan Cosmetics division. Clarins "remains open to possible new ventures, either with P&G with whom discussions are continuing, or with other partners," the company states. With combined sales of approximately $50 mil. in the U.S. in 2004, Clarins' own Thierry Mugler and Azzaro brands "have now reached the critical mass that justifies an independent structure," the firm says, adding the futures of those brands are not in question...

You may also be interested in...



Hugo Boss Scent Portfolio Grows With Boss Soul, Del Mar Offerings

The launch of Boss Soul, the latest men's scent under the Hugo Boss franchise, will be supported with an aggressive promotional campaign, according to Clarins, the brand's U.S. distributor

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

UsernamePublicRestriction

Register

RS012270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel